These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 27884496)

  • 21. Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes?
    Burgmaier M; Heinrich C; Marx N
    Diabet Med; 2013 Mar; 30(3):289-99. PubMed ID: 22804451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
    Morales J
    Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin and glucagon-like peptide receptor agonist (GLP 1 RA) combinations.
    Kalra S
    J Pak Med Assoc; 2014 Mar; 64(3):359-61. PubMed ID: 24864619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Modulation of the incretin effect in the treatment of diabetes].
    Vidal J
    Med Clin (Barc); 2014 Sep; 143 Suppl 2():8-11. PubMed ID: 25437459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular effects of incretins in diabetes.
    Advani A; Bugyei-Twum A; Connelly KA
    Can J Diabetes; 2013 Oct; 37(5):309-14. PubMed ID: 24500557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Are basal and glucagon-stimulated C-peptide values predictors of response to GLP-1 receptor agonists in type 2 diabetic patients?
    Maiza JC; Gérard P; Rollot O; Cogne M; Jarlet E; Schneebeli S
    Minerva Endocrinol; 2016 Mar; 41(1):138-40. PubMed ID: 26878563
    [No Abstract]   [Full Text] [Related]  

  • 27. Newer GLP-1 receptor agonists and obesity-diabetes.
    Brown E; Cuthbertson DJ; Wilding JP
    Peptides; 2018 Feb; 100():61-67. PubMed ID: 29412833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Characteristics and types of GLP-1 receptor agonists. An opportunity for individualized therapy].
    Jódar E
    Med Clin (Barc); 2014 Sep; 143 Suppl 2():12-7. PubMed ID: 25437460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delivery Device Patents on GLP-1 Receptor Agonists.
    Alhiary R; Gabriele S; Kesselheim AS; Tu SS; Feldman WB
    JAMA; 2024 Mar; 331(9):794-796. PubMed ID: 38315473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical use of GLP-1 agonists and DPP4 inhibitors.
    Tuch BE
    Pancreatology; 2016; 16(1):8-9. PubMed ID: 26138513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Diabetes therapy--novel drugs to come (DPP-4 inhibitors, GLP-1 agonists, SGLT-2 inhibitors)].
    Gallwitz B
    MMW Fortschr Med; 2010 May; 152(20):43-4. PubMed ID: 20552881
    [No Abstract]   [Full Text] [Related]  

  • 32. Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors.
    Suzuki R; Brown GA; Christopher JA; Scully CCG; Congreve M
    J Med Chem; 2020 Feb; 63(3):905-927. PubMed ID: 31577440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.
    Madsbad S; Krarup T; Deacon CF; Holst JJ
    Curr Opin Clin Nutr Metab Care; 2008 Jul; 11(4):491-9. PubMed ID: 18542012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucagon-like peptide-1 analogs: Miracle drugs are blooming?
    Gong B; Yao Z; Zhou C; Wang W; Sun L; Han J
    Eur J Med Chem; 2024 Apr; 269():116342. PubMed ID: 38531211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endogenous glucagon-like peptide (GLP)-1 as alternative for GLP-1 receptor agonists: Could this work and how?
    Smits MM; Holst JJ
    Diabetes Metab Res Rev; 2023 Nov; 39(8):e3699. PubMed ID: 37485788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insertion of an N-terminal 6-aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-acting hypoglycemic agent.
    Doyle ME; Greig NH; Holloway HW; Betkey JA; Bernier M; Egan JM
    Endocrinology; 2001 Oct; 142(10):4462-8. PubMed ID: 11564711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The current significance and prospects for the use of dual receptor agonism GLP-1/Glucagon.
    Spezani R; Mandarim-de-Lacerda CA
    Life Sci; 2022 Jan; 288():120188. PubMed ID: 34861287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.
    Wong C; Lee MH; Yaow CYL; Chin YH; Goh XL; Ng CH; Lim AYL; Muthiah MD; Khoo CM
    Front Endocrinol (Lausanne); 2021; 12():609110. PubMed ID: 33897616
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes: BMJ Rapid Recommendation.
    Arnold MJ; Buelt A
    Am Fam Physician; 2022 Jun; 105(6):675-677. PubMed ID: 35704807
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.